Corcept Therapeutics (CORT)

Executive Summary

Corcept Therapeutics is a commercial-stage biopharmaceutical company focused on selective cortisol modulators targeting the glucocorticoid receptor (GR). Its approved product, Korlym (mifepristone), is indicated for Cushing's syndrome and provides a steady revenue stream. The company's pipeline is anchored by relacorilant, a next-generation GR modulator that has completed Phase 3 testing in hypercortisolism (Cushing's) with positive results, positioning it for potential NDA submission. Corcept is also exploring relacorilant in oncology, including a Phase 1/2 trial in prostate cancer combined with enzalutamide, and earlier-stage assets for neurologic and metabolic indications. With a strong cash position and a focused strategy, Corcept is well-positioned to expand its franchise in cortisol modulation. Near-term catalysts include the potential NDA submission for relacorilant in Cushing's syndrome, which could drive significant revenue growth. Additionally, data readouts from ongoing oncology trials may open new indications. The company's conviction is high given its commercial execution and robust pipeline, though regulatory and clinical risks remain.

Upcoming Catalysts (preview)

• Q3 2026NDA Submission for Relacorilant in Cushing's Syndrome80% success
• H2 2026Phase 2 Data for Relacorilant in Advanced Solid Tumors60% success
• 2027Phase 3 Start for Relacorilant in Prostate Cancer50% success